Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
During the last three months, 5 analysts shared their evaluations of Janux Therapeutics (NASDAQ:JANX), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 1 | 2 | 2 | 0 | 0 |
Last 30D | 0 | 0 | 1 | 0 | 0 |
1M Ago | 0 | 2 | 0 | 0 | 0 |
2M Ago | 0 | 0 | 0 | 0 | 0 |
3M Ago | 1 | 0 | 1 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $65.2, a high estimate of $100.00, and a low estimate of $42.00. A decline of 3.76% from the prior average price target is evident in the current average.
In examining recent analyst actions, we gain insights into how financial experts perceive Janux Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
George Farmer | Scotiabank | Lowers | Sector Perform | $42.00 | $47.00 |
Josh Schimmer | Cantor Fitzgerald | Maintains | Overweight | $100.00 | $100.00 |
Robert Driscoll | Wedbush | Maintains | Outperform | $74.00 | $74.00 |
George Farmer | Scotiabank | Announces | Sector Perform | $47.00 | - |
Swayampakula Ramakanth | HC Wainwright & Co. | Raises | Buy | $63.00 | $50.00 |
Capture valuable insights into Janux Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Janux Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Janux Therapeutics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 741.72% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Janux Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -66.98%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Janux Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -0.91%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Janux Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of -0.86%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Janux Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.04, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: JANX